retatrutide ada 2025 results Provides Substantial Weight Loss in Patients With Obesity or Overweight Retatrutide and the Grey Market:

Cell Rep Med 4(11) Dankner R, Murad H, Agay N, Olmer L, Freedman LS (2024) Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes

Who Profits: Eli Lilly (LLY) FY2025 Revenue: $63.5B | GLP-1 Revenue (Mounjaro + Zepbound): $35-38B (estimated) | Operating Margin: 31% | CEO (David Ricks): $24.3M This issue's mechanism: Eli Lilly is winning the market share battle against Novo

Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database

Patients are coming in feeling healthier, more confident, and excited about their progress, says Dana Baker, RN